A Study to Evaluate the Safety and Efficacy of SH-1028 in Locally Advanced or Metastatic NSCLC

NCT03823807 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

300

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: SH-1028

Sponsor

Nanjing Sanhome Pharmaceutical, Co., Ltd.